Literature DB >> 28893792

Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients.

Susanna Edith Medellín-Garibay1, Silvia Romano-Moreno2, Pilar Tejedor-Prado3, Noelia Rubio-Álvaro3, Aida Rueda-Naharro3, Miguel Angel Blasco-Navalpotro3, Benito García3, Emilia Barcia1.   

Abstract

Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], -0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  dosing recommendations; intensive care; mechanical ventilation; population pharmacokinetics; stochastic simulations; vancomycin

Mesh:

Substances:

Year:  2017        PMID: 28893792      PMCID: PMC5700364          DOI: 10.1128/AAC.01249-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  Pulmonary disposition of vancomycin in critically ill patients.

Authors:  H Georges; O Leroy; S Alfandari; B Guery; M Roussel-Delvallez; C Dhennain; G Beaucaire
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 3.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 4.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

6.  Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Andrew A Udy; Jean-Louis Vincent; Frédérique Jacobs; Jeffrey Lipman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

7.  Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

8.  Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections.

Authors:  Ayesha J Verrall; Ryan Llorin; Vincent H Tam; David C Lye; Zuraidah Sulaiman; Lihua Zhong; Sophia Archuleta; Dale A Fisher
Journal:  J Antimicrob Chemother       Date:  2012-08-21       Impact factor: 5.790

9.  Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin.

Authors:  R Minkutė; V Briedis; R Steponavičiūtė; A Vitkauskienė; R Mačiulaitis
Journal:  J Clin Pharm Ther       Date:  2013-08-08       Impact factor: 2.512

10.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17
View more
  8 in total

1.  Is Alternate-Day Therapeutic Drug Monitoring in the Intensive Care Unit Not Intensive Enough?

Authors:  Parviz Sorooshian; Timothy A C Snow
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

2.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients.

Authors:  Tingjie Guo; Reinier M van Hest; Luca F Roggeveen; Lucas M Fleuren; Patrick J Thoral; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 3.  An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.

Authors:  Abdullah Aljutayli; Amélie Marsot; Fahima Nekka
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

4.  Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Xiangqing Song; Meizi Zeng; Yi Wu; Yong Pan
Journal:  Front Microbiol       Date:  2021-04-22       Impact factor: 5.640

5.  Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function.

Authors:  Siriluk Jaisue; Cholatip Pongsakul; David Z D'Argenio; Pakawadee Sermsappasuk
Journal:  Ther Drug Monit       Date:  2020-12       Impact factor: 3.118

6.  Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels.

Authors:  Radica Zivkovic Zaric; Jasmina Milovanovic; Nikola Rosic; Dragan Milovanovic; Dejana Ruzic Zecevic; Marko Folic; Slobodan Jankovic
Journal:  Open Med (Wars)       Date:  2018-10-22

7.  Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients.

Authors:  Shifeng Wei; Dongjie Zhang; Zhigang Zhao; Shenghui Mei
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

8.  Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.

Authors:  Nyein Hsu Maung; Janthima Methaneethorn; Thitima Wattanavijitkul; Tatta Sriboonruang
Journal:  Eur J Hosp Pharm       Date:  2021-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.